The use of ligand mAbs as an approach to limit toxicity and hyperglycemia, while inhibiting IGF-1R/INSR-A mediated effects of tumor proliferation and survival, was supported by a Phase I trial using MEDI-573 (228). This evidence concerns the gene IGF1R and neoplasm.